BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

ABSTRACT:

Background

As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel's largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine.

Methods

All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics. Study outcomes included documented infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), symptomatic Covid-19, Covid-19-related hospitalization, severe illness, and death. We es

SUBMITTER: Dagan N 

PROVIDER: S-EPMC7944975 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature